Table 1.

Baseline characteristics of adolescents and adults with newly diagnosed BL in Lilongwe, Malawi, from 2013 to 2018

Total no. of patientsAllHIV-positive (n = 15)HIV-negative (n = 20)P
No.%MedianRangeMeanSDNo.%MedianRangeMeanSDNo.%MedianRangeMeanSD
Male sex 35 25 71     10 67     15 75     .71 
Age, y 35   21 15-61     40 21-61     15 15-41   <.001 
Body mass index, kg/m2 30     19.1 4.5     21.8 3.1     16.2 3.9 <.001 
B symptoms 35 24 69     10 67     14 70     1 
Ann Arbor stage III to IV 35 27 77     9 60     18 90     .05 
ECOG PS ≥2 35 19 54     5 33     14 70     .04 
aaIPI 32                   .28 
 0  1 3     1 7     0 0     
 1  7 22     5 33     2 12      
 2  12 38     5 33     7 41      
 3  12 38     4 27     8 47      
Central nervous system involvement 35 5 14     1 7     4 20     .36 
Bone marrow involvement 22 4 18     2 50     2 15     1.00 
Abdominal disease 35 23 66     7 47     16 80     .07 
Bulky disease (>10 cm) 24 16 66     9 60     7 78     .66 
HIV diagnosis known prior to Burkitt diagnosis 15 ―      9 60     ―      ― 
Time since HIV diagnosis, years 9  ―       1.4 0.4-9.4    ―     ― 
Receiving ART at BL diagnosis 15 ―      8 53     ―      ― 
Duration of ART at BL diagnosis, years 8  ―       1.1 0.4-2.6    ―     ― 
CD4 count, cells per μL 15  ―       130 29-605    ―     ― 
HIV viral load, log10 copies per μL 15  ―       1.6 0-6.0    ―     ― 
HIV viral load, detectable >400 copies per μL 15 ―      5 33     ―      ― 
White blood cells, ×109/L 35   7.2 2.1-20.3     4.8 2.1-12.0     8.3 3.6-20.3   .005 
Hemoglobin, g/dL 35   10.8 1.6-14.8     11.0 7.7-14.8     9.8 1.6-14.3   .17 
Platelets, ×109/L 35   365 77-859     312 77-791     382 139-859   .44 
Creatinine, mg/dL 33   0.6 0.3-28.0     0.8 0.6-28.0     0.5 0.3-11.4   .002 
Bilirubin, mg/dL 32   0.3 0.2-2.0     0.3 0.2-1.4     0.4 0.2-2.0   .05 
Albumin, g/dL 26     3.7 0.8     3.8 0.8     3.6 0.9 .69 
LDH ratio per ULN 32   2.2 0.4-22.3     3.0 0.7-22.3     2.1 0.4-20.0   .35 
LDH >2× ULN 32 22 67     11 73     11 65     .71 
EBER positive by in situ hybridization 19 9 47     2 20     7 78     .02 
First-line chemotherapy 31                   1.00 
 CHOP  22 71     9 75     13 68      
 More intensive  9 29     3 25     6 32      
Total no. of patientsAllHIV-positive (n = 15)HIV-negative (n = 20)P
No.%MedianRangeMeanSDNo.%MedianRangeMeanSDNo.%MedianRangeMeanSD
Male sex 35 25 71     10 67     15 75     .71 
Age, y 35   21 15-61     40 21-61     15 15-41   <.001 
Body mass index, kg/m2 30     19.1 4.5     21.8 3.1     16.2 3.9 <.001 
B symptoms 35 24 69     10 67     14 70     1 
Ann Arbor stage III to IV 35 27 77     9 60     18 90     .05 
ECOG PS ≥2 35 19 54     5 33     14 70     .04 
aaIPI 32                   .28 
 0  1 3     1 7     0 0     
 1  7 22     5 33     2 12      
 2  12 38     5 33     7 41      
 3  12 38     4 27     8 47      
Central nervous system involvement 35 5 14     1 7     4 20     .36 
Bone marrow involvement 22 4 18     2 50     2 15     1.00 
Abdominal disease 35 23 66     7 47     16 80     .07 
Bulky disease (>10 cm) 24 16 66     9 60     7 78     .66 
HIV diagnosis known prior to Burkitt diagnosis 15 ―      9 60     ―      ― 
Time since HIV diagnosis, years 9  ―       1.4 0.4-9.4    ―     ― 
Receiving ART at BL diagnosis 15 ―      8 53     ―      ― 
Duration of ART at BL diagnosis, years 8  ―       1.1 0.4-2.6    ―     ― 
CD4 count, cells per μL 15  ―       130 29-605    ―     ― 
HIV viral load, log10 copies per μL 15  ―       1.6 0-6.0    ―     ― 
HIV viral load, detectable >400 copies per μL 15 ―      5 33     ―      ― 
White blood cells, ×109/L 35   7.2 2.1-20.3     4.8 2.1-12.0     8.3 3.6-20.3   .005 
Hemoglobin, g/dL 35   10.8 1.6-14.8     11.0 7.7-14.8     9.8 1.6-14.3   .17 
Platelets, ×109/L 35   365 77-859     312 77-791     382 139-859   .44 
Creatinine, mg/dL 33   0.6 0.3-28.0     0.8 0.6-28.0     0.5 0.3-11.4   .002 
Bilirubin, mg/dL 32   0.3 0.2-2.0     0.3 0.2-1.4     0.4 0.2-2.0   .05 
Albumin, g/dL 26     3.7 0.8     3.8 0.8     3.6 0.9 .69 
LDH ratio per ULN 32   2.2 0.4-22.3     3.0 0.7-22.3     2.1 0.4-20.0   .35 
LDH >2× ULN 32 22 67     11 73     11 65     .71 
EBER positive by in situ hybridization 19 9 47     2 20     7 78     .02 
First-line chemotherapy 31                   1.00 
 CHOP  22 71     9 75     13 68      
 More intensive  9 29     3 25     6 32      

aaIPI, age-adjusted International Prognostic Index; EBER, Epstein-Barr virus–encoded RNA; SD, standard deviation.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal